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Drug resistance negatively impacts malaria treatments, making treatment policy revision unavoidable. So far, studies relating
sociopolitical and technical issues on policy change with malaria parasite genetic change are lacking. We have quantiﬁed the eﬀect
of malaria treatment policy on drug pressure and the inﬂuence of the media, policy makers, and health worker relationship on
parasite population genetic change in Kilombro/Ulanga district. Cross-sectional surveys of asymptomatic infections conducted
before, during and after the switch from chloroquine to sulphadoxine/pyrimethamine were used for genetic analysis of SP
resistance genes in 4,513 asymptomatic infections identiﬁed, and their frequency change was compared with retrospective study of
the documented process of policy change. Highly signiﬁcant changes of dhfr and dhps resistance alleles occurred within one year of
switch to SP ﬁrst line, followed by a decline of their rate of selection caused by reduction of SP usage, as a result of negative media
r e p o r t so nS Pu s a g ea n dl a c ko fa d e q u a t ep r e p a r a t i o n s .
1.Introduction
Malaria remains the world’s most important tropical par-
asitic disease and one of the major public health chal-
lenges in the poorest countries of the world, particularly
in sub-Saharan Africa, as the prospect of an eﬀective
vaccine remains uncertain. Although some African coun-
tries have increased their spending in health along with
the support from the Global Fund to Fight AIDS, TB,
and Malaria (GFATM) and other partners, development
assistance has been routed largely through public channels,
whereas aﬀected individuals seek treatment mostly through
the private sector [1]. Consequently, the rising cost of
medical services and the increasing trends of drug resistance
raise critical public health concerns, as this constrains the
provision of adequate health care in countries where the
disease is endemic [1]. Evidence on Plasmodium falciparum
resistance to chloroquine (CQ) between 1980s and early
2000 prompted most countries where malaria is endemic to
revise their treatment guidelines, most of them replacing it
with sulfadoxine-pyrime (SP) [2, 3]. In Tanzania, CQ was
oﬃcially replaced with SP in 2001, apparently as an interim
policy [4]. However, SP resistance became widespread
shortly after its adoption as ﬁrst-line treatment, because its
resistance had already been established in Tanzania and the
neighbouring countries [5–8], and also, because it had been
used as the second-line treatment for malaria in Tanzania
until 2001, when it became the ﬁrst-line treatment drug. Its2 Malaria Research and Treatment
long half-life could also have contributed to the observed
rapid development of resistance [9]. Most malaria endemic
countries replaced SP with artemisinin-based combination
therapy (ACT) between the year 2002 and 2008. Tanzania
replaced SP with artemether + lumefantrine (ALU) as the
ﬁrstline national antimalarial treatment in 2006.
Treatment of malaria in Tanzania is typically guided
by oﬃcial recommendations from the Ministry of Health
and Social Welfare (MOHSW) regarding drugs of choice
for various situations. “First-line” treatment refers to the
drug oﬃcially recommended as the drug of ﬁrst choice
for the treatment of uncomplicated malaria. “Second-line”
treatment refers to the drug oﬃcially recommended as an
alternative primarily to be used for treatment of patients in
whomtheﬁrst-linetreatmentfailedtocleartheinfectionand
other select patients (such as those who are hypersensitive
to the ﬁrst-line treatment). “Third-line” treatment typically
refers to the drug recommended for severely ill patients
(a rescue drug). In practice, few treatment failures are
recognized, and patients are often moved directly from ﬁrst
to third-line treatment, consequently, little second-line drug
is used compared to the ﬁrst-line drug. SP replaced CQ
as the recommended ﬁrst-line treatment on the Tanzanian
mainlandinAugust2001,after18yearsofitsuseasasecond-
line treatment since 1983.
Policy change is both an expensive and diﬃcult process,
and many endemic countries are already faced with diﬃcult
decisions on how to replace ineﬀective antimalarial drugs in
use with more eﬃcacious, but also more costly alternatives.
One of the greatest challenges in this decision-making
process is the fear that resistance will develop rapidly to
the replacement drug, initiating an endless cycle of drug
replacement and escalating costs.
Studies conducted one year after adoption of SP as the
ﬁrst-line antimalarial treatment policy in Tanzania indicate
that inadequate evidence-based education and sensitization
of health workers together with negative media reports
negatively impacted the adoption of the new policy [4, 10,
11].
Theory predicts that we can protect the eﬃcacy of future
antimalarials by changing treatment practice or drug formu-
lation, but the potential success of such interventions rests
upon their impact on drug pressure in the ﬁeld [12]. Math-
ematical models [13] predict that drug coverage/extensive
drug usage is the primary determinant of drug pressure, and
the driving force behind the evolution of drug resistance [14,
15]. Research ﬁndings have established that resistance to CQ
and SP results from accumulation of multiple mutations in
the respective target gene(s). Once formed, these mutations
spread within and between continents [8, 16–18].
We have systematically followed the rate of selection of
SP resistance alleles in a one-year prior and ﬁve years after
adoption of SP as the ﬁrst-line antimalarial treatment in
Tanzania. From the molecular genetics perspective, we show
that the trend displayed by resistant alleles together with
linkage disequilibrium between double dhps and triple dhfr
resistant alleles correlates with published reports of media
[4, 10, 11] and health worker’s inﬂuence on policy adoption
[4].
2.MaterialsandMethods
2.1. Study Area, Subjects, and Samples. Community surveys
were conducted during July, August, and September of 2000,
2001, 2002, 2004, 2005, and 2006 in Kilombero (population.
= 220,000) and Ulanga (population = 160,000). The surveys
were part of a large combination therapy pilot implemen-
tation programme in Tanzania, the Interdisciplinary Mon-
itoring Programme for Antimalarial Combination Therapy
(IMPACT-TZ). For the purpose of the study, Kilombero and
Ulanga districts were treated as a single district, because
populationmovementbetweenthesetwodistrictsishighand
the study population spans the border region. Plasmodium
falciparum malaria transmission in the study area is intense
(with an estimated entomological inoculation rate of 367
infectious bites per person per year [19] and perennial with
some seasonal ﬂuctuation). A total of 24,212 adults and chil-
drenbelongingtorandomlyselectedhouseholdsparticipated
in the study. A ﬁnger-prick blood sample for blood slide and
ﬁlter paper bloodspot were collected from each individual
in the household. The ﬁlter paper bloodspots were air-dried
and put in self-sealing plastic bags with desiccant and stored
on dry area at room temperature. All blood slide samples
were screened by microscopy for P. falciparum. Bloodspots
from microscopically positive subjects were selected and
preserved at room temperature for molecular genotyping.
2.2. Antimalarial Drug Policy. Prior to the ﬁrst national
antimalarial policy change in Tanzania in August 2001,
the ﬁrst-line treatment drug was CQ, SP was the second-
line, while quinine (Q) was the third-line treatment. The
policy change replaced CQ with SP as ﬁrst-line treatment
and SP was replaced with amodiaquine (AQ) as second-
line treatment, while Q continued serving as the third-
line treatment. Issues surrounding the 2001 policy change
are detailed in [4]. The policy decision was supported by
research evidence indicating an intolerable parasite resis-
tance to CQ and clinical CQ treatment failure rates of above
52%, as compared to SP and AQ failure rate of about 9.5%
and less than 4.6%, respectively. Research also indicated that
since SP was also facing rising resistance trend, the need
for a more eﬀective drug was indispensable, but for an
interim 5–10-year period, it was justiﬁable to recommend
SP that was relatively more cost eﬀective than CQ and AQ.
The government launched the policy change considering
that studies (ethically approved by the Ministry of Health)
on therapeutic eﬃcacy and cost eﬀectiveness of artemisinin
drug combination therapies were underway. Nevertheless,
the process of communicating research results and recom-
mendations to policy-making authorities involved critical
debates between policy makers and researchers, among the
researchers themselves and between the researchers and
general practitioners, the speculative media reports on SP
side eﬀects and reservations by the general public concerning
therationaleforpolicychange,whentochange,andtowhich
drug of choice.
The second national antimalarial policy change was
implemented in 2006, whereby artemether and lumefantrine
(ALU) replaced SP as the ﬁrst-line treatment. However, theMalaria Research and Treatment 3
policy remained silent about the second-line and the third-
line treatments although in practice, Q is used as both the
second-line and rescue drug, because when a patient on ALU
therapy fails to clear parasite, he/she is moved straight to Q.
Overall, while the dynamics surrounding the govern-
ment’s policy to replace CQ with SP in 2001 have been well
documented [4], there is very little published data on the
process of change from SP to ALu. The evidence supporting
thechangecamefromanumberofinvitroandinvivostudies
showing unacceptable levels of parasite resistance to SP and
the IMPACT-Tanzania studies which piloted the use of ACT
in rural Tanzania [20].
2.3. Ethical Consideration. Scientiﬁc and ethical clearance
was granted from the Medical Research Council of the
National Institute for Medical Research in Tanzania, the
Centers for Disease Control and Prevention, USA, and the
London School of Hygiene and Tropical Medicine. Consent
was obtained from all individuals or their guardians before
collection of samples.
2.4. DNA Extraction. The DNA was extracted from blood-
spots dried on ﬁlter papers. A section of the dried blood spot
ﬁlter paper was excised using a sterile blade or scissors and
soaked in a 1mL of 0.5% saponin in 1x phosphate buﬀered
saline (PBS) overnight in a 96-deepwell plate. The segment
was then washed twice in 1mL of 1x PBS and was ﬁnally
b o i l e df o r8m i ni n1 0 0µL PCR quality water with 50µLo f
20% chelex suspension (pH 9.5).
2.5. PCR Ampliﬁcation. Nested PCR was used to amplify a
594 base pair (bp) fragment of dhfr and a 711bp fragment
of dhps each containing the sequence, where mutations
are found. Primer sequences and PCR reaction conditions
were previously described in [7]. PCR was performed in
96 well plates with 25-µL PCR reaction volumes containing
ﬁnal concentrations of 0.25µM oligonucleotide primers,
2mM MgCl 2, 250µM each deoxyribonucleotide triphos-
phate (dNTPs), and 1x Taq polymerase. 1µLo fD N At e m -
plate was used in the outer (primary) PCR reaction mixture
for dhfr and dhps ampliﬁcations. For the inner (secondary)
dhps reactions 1µL of the outer PCR product was used. The
outerdhfr PCRproductsweredilutedthreefoldbeforea1µL
was introduced into the inner PCR reaction mixtures.
2.6. Molecular Genotyping of Point Mutations by Sequence
Speciﬁc Oligonucleotide Probing (SSOP). The ampliﬁed PCR
products were screened for dhfr and dhps sequence variants
at 10 loci, where single nucleotide polymorphisms (SNPs)
are known. The sequence changes (and the amino acid
substitutions they code for) are summarised in Table 1.
PCR products were spotted in a 12 by 8-grid and cross
linked onto nylon membranes and probed for sequence
polymorphisms by hybridisation to speciﬁc oligonucleotide
probes described previously [7]. For analysis of samples
collectedin2000,thevisualizationofhybridiseddigoxygenin
labelledprobesonmembraneswasperformedbythealkaline
phosphatase-catalysed breakdown of the CSPD substrate
Table 1: The nucleotide and amino acid substitutions at (a) dhfr
and (b) dhps genes screened for by PCR-SSOP.
(a) dhfr
Codon 50 51 59 108 164
Wild type
Cys (C) Asn (N) Cys (C) Ser (S) Ile (I)
TGT AAT TGT AGC ATA
AAC
Mutant
Arg (R) Ile (I) Arg (R) Asn (N) Leu (L)
CGT ATT CGT AAC TTA
Thr (T)
ACC
(b) dhps
Codon 436 437 540 581 613
Wild type Ser (S) Ala (A) Lys (K) Ala (A) Ala (A)
TCT GCT AAA GCG GCC
Mutant
Phe (F) Gly (G) Glu (E) Gly (G) Ser (S)
TTT GGT GAA GGG TCC
Ala (A) Thr (T)
GCT ACC
Cys (C)
TGT
(Roche Boehringer Mannheim, Mannheim, Germany) and
visualised by exposure on Hyperﬁlm-ECL (Amersham Phar-
macia Biotech, Little Chalfont, Buckinghamshire, United
Kingdom), according to Boehringer Mannheim recommen-
dations and previously described in [21]. For analysis of
samples collected in 2001 and 2002, the probed blots
were visualised using ECF substrate and detection using a
phosphoimager (STORM). Inspection of autoradiographic
ﬁlms was carried out by light box illumination, while the
phosphoimager output was recorded through viewing of
digitally captured images of chemiﬂourescent signal. The
change in the method by which probe hybridisation signal
was visualised did not aﬀect the results in any way since the
probes and hybridisation conditions were unchanged.
The stringency and speciﬁcity of the hybridisation pro-
cesswasconﬁrmedbyinspectionofaseriesof4controlswith
a known single genotype variant sequence. All blots with
nonspeciﬁcally bound probes were stripped and reprobed.
A SNP was considered to be present in the PCR product
when the intensity of signal was higher than that of the back-
ground. The blots were scored independently by two people.
In our analysis, we aimed to establish the relative
abundance of diﬀerent point mutation haplotypes at dhfr
and dhps. Since bloodstage P. falciparum is haploid, this is
very straightforward when an infection consists of a single
genotype, because only one form of sequence at every SNP
locus is seen. When infections are composed of multiple
genotypes a mixture of diﬀerent sequence variants occur
making the inference of point mutation haplotypes within
that infection more diﬃcult.
The presence, absence, and relative abundance of
hybridisation signals for every probe were recorded at each4 Malaria Research and Treatment
Table 2: Annual survey population, proportions that were malaria positive and their PCR ampliﬁcation outcome for the period between
2000–2006 in Kilombero/Ulanga population.
2000 2001 2002 2004 2005 2006
Survey population 3,289 3,197 4,098 4,122 5,006 4,500
P. falciparum positive 955 580 875 972 486 645
PCR ampliﬁed dhfr 404 488 686 660 374 294
PCR ampliﬁed dhps 444 347 720 712 407 323
Single or majority dhfr 376 238 489 540 267 275
Single or majority dhps 365 294 603 562 293 275
Single or majority d h f r+d h p s 190 138 381 381 283 206
locus. A sample was considered to have a single haplotype
when only one sequence variant was found at each locus.
Blood samples were categorised as having a single, a majority
or a mixture of sequence at every SNP locus. Majority and
mixed genotype infections were diﬀerentiated according to
the relative intensity of signal. To determine the relative
abundance of diﬀerent point mutation haplotypes in the
parasite population, only one haplotype was counted from
each infection and those mixed infections, where haplotypes
could not be resolved were omitted from the calculation
of haplotype frequencies. Hence, frequency data is based
upon a subset of isolates which were unmixed or had a
predominating majority haplotype. A breakdown of the
proportions of isolates which were successfully PCR ampli-
ﬁed and genotyped as single, majority or mixed haplotype
infections is given in Table 2.
2.7. Statistical Analysis. Statistical comparison of allele fre-
quencies at dhfr and dhps in the various sites was carried
out using chi-squared analysis in STATA version 9.2. The
calculation of binomial exact 95% conﬁdence intervals was
carried out using STATA version 9.2. Linkage disequilibrium
analysis was performed using Arlequin software.
3. Results
24,212 people were sampled and 4,513 asymptomatic infec-
tions identiﬁed. DNA was extracted from the 4,513 P. falci-
parum positive bloodspots and PCR of dhfr and dhps per-
formed once, giving a combined rate of PCR ampliﬁcation
success of 69% for both genes (Table 2). The ampliﬁed prod-
ucts were screened for all the variant sequences described in
Table 1. Out of the 2,906 isolates which ampliﬁed for dhfr,
2,185 (75%) were single or majority genotype infections and
the point mutation haplotypes could easily be resolved. Of
the 2,953 samples which ampliﬁed for dhps, 2,392 (81%)
were single or majority genotype with resolvable haplotypes.
3.1. Allelic Haplotypes at dhfr and dhps Genes. The point
mutations found in the dhfr gene were N51I, C59R, and
S108N as reported elsewhere [12]. They were found in
the following haplotypic arrangements CNCSI, CNCNI,
CNRNI, CICNI, and CIRNI which are reported to be
common throughout Eastern Africa, Tanzania [7], Malawi
[22], Kenya [5, 23] and Uganda [24, 25].
Five mutations were found at dhps; S436A, S436F, S436C,
A437G, and K540E as reported elsewhere [12]. These were
found in nine distinct haplotypic arrangements; ﬁve of
which(SAKAA,AAKAA,SGEAA,SGKAA,andSAEAA)were
described previously in isolates from East Africa [5, 7, 23–
25]whiletheremainingfour(CAKAA,FAKAA,AAEAA,and
FAEAA) were found in extremely low frequency and have not
been reported before, presumably because of their rarity.
3.2. Haplotypes Conferring High Levels of Resistance. The
dhfr CIRNI haplotype and the dhps SGEAA haplotype have
the greatest signiﬁcance for SP eﬃcacy; their frequency in
the six successive surveys displayed three distinct phases as
shown in Figures 1 and 2. Changes occurring under the
CQ policy (phase 1: 2000 to 2001) are markedly diﬀerent to
those occurring under the SP policy (phase 2: 2001-2002).
Likewise, the frequency of the dhps double mutant A437G
K540E (shown in Figure 2) did not change signiﬁcantly in
phase 1, between 2000 and 2001 (P ≥ .497). Contrastingly,
there was a highly signiﬁcant change in phase 2, between
2001 and 2002 (P ≤ .0001) (95% CI). In phase 3, between
2002 and 2006 both the dhfr triple and the dhps double
mutant alleles showed a marked retarded rate of selection of
the two unlinked resistant alleles.
In a further subset of samples, where dhfr and dhps
haplotypes were both conclusively resolved, it was possible
to measure the frequency of two locus genotypes.
In Figure 3,thefrequencyofthetripledhfr +d oubledhps
genotype for the six successive surveys is presented. As for
the case of the dhfr triple and the dhps double mutant alleles,
the triple dhfr +d o u b l edhps genotype showed three distinct
phases. The frequency was around 0.05 in phase one and
there was no change between 2000 and 2001 (P ≥ .824) but
a remarkable 5 fold increase to frequency of 0.28 occurred
in phase two between 2001 and 2002 (P ≤ .0001). In phase
three, this two locus genotype (the triple dhfr +d o u b l e
dhps) was characterised by a marked reduction of the rate
of selection between 2002 to 2006.
3.3. Haplotypes Conferring Intermediate Levels of Resistance.
As well as the highly resistant dhps A437G K540E double
mutant,anumberofsingle436mutantalleleswererecorded.Malaria Research and Treatment 5
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Figure 1: Changes in the frequency of pyrimethamine resistance
gene (dhfr) in Kilombero/Ulanga in six successive surveys (2000–
2006).
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Figure 2: Changes in the frequency of Sulfadoxine resistance gene
(dhps) in Kilombero/Ulanga between 2000–2006.
Amongthese,byfarthemostcommonwastheS436A,which
was consistently found at frequencies of 10%–20% in all
six successive surveys. Figure 2 shows the frequencies of the
sensitive S436A single mutant and the A437G K540E double
mutant alleles through time. From these data, it is clear that
theincreased frequencyofthe double mutant alleledisplaced
thesensitiveallele,whichdecreasednonsigniﬁcantlyin2000-
2001 (P ≥ .791) and signiﬁcantly in 2001-2002 (P ≥ .003).
Interestingly, the frequency of the A436A allele remained
static in all time points in both districts.
The eﬀect of drug policy changes on the frequency
of sensitive and double mutant dhfr alleles is shown in
Figure 1. The increase of the triple mutant allele acted to
displace sensitive alleles which showed a substantial but non
signiﬁcant decline in phase one (2000-2001) and phase three
(2002–2006) (P ≥ .352) and a highly signiﬁcant decline in
phase two (2001-2002) (P ≤ .0001). The double mutant
dhfr alleles, which confer intermediate levels of resistance in
vitro [26], neither increased nor decreased, remaining at a
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Figure 3: Changes in the frequency of the two locus genotype
combination, dhfr triple + dhps double mutant allele in Kilo-
mbero/Ulanga in six successive surveys (2000–2006).
Table 3: The trend of the D’ values (an index of linkage
disequilibrium) and their P values in the period between 2000 and
2006 in Kilombero/Ulanga population.
Year of survey Kilombero/Ulanga
D  P
2000 −0.5333 .3307
2001 0.0417 .7539
2002 0.3633 .00001∗∗∗∗
2004 0.2948 .0001∗∗∗
2005 0.2595 .0001∗∗∗
2006 0.0814 .2686
∗Indicates degree of signiﬁcance.
frequency of around 10% in both districts throughout all
surveys.
3.4. Linkage Disequilibrium (LD). To examine the eﬀect
of simultaneous selection by pyrimethamine on dhfr and
sulphadoxine on dhps, we looked at two-locus genotypes
sampled from Kilombero/Ulanga in the six successive sur-
veys. Taking the subset of samples for which point muta-
tion haplotypes could be unequivocally resolved for both
genes, we compared the observed with expected frequencies
generated from contingency tables. No signiﬁcant linkage
disequilibrium was found between dhfr and dhps loci in
either 2000 (D  =− 0.5333, P ≥ .3307) or 2001 (D  =
0.0417, P ≥ .75339) indicating that the drug selection
pressure was insuﬃcient to overcome the force of recom-
bination. However, a highly signiﬁcant LD (D  = 0.3633,
P ≤ .00001) was observed in 2002 indicating that the drug
selectionpressurewasalreadysuﬃcientlyhighertoovercome
the eﬀect of recombination. The degree of signiﬁcance of
the LD started to show a decline in 2004 (D  = 0.2948,
P ≤ .00001) and 2005 (D  = 0.2595, P ≤ .00001), and
by 2006, there was no more signiﬁcant LD (D  = 0.0814,
P ≥ .2686) (Table 3). This indicates that there was a gradual
decline in drug pressure between 2002 and 2006.
4. Discussion
This study has generated results of six-year followup of
dhfr and dhps genetic changes in the P. falciparum in two6 Malaria Research and Treatment
rural districts of south eastern Tanzania. A high through-
put sequence speciﬁc olignucleotide method was used to
genotype point mutations present at the SP resistance genes,
the dhfr and dhps in population samples of P. falciparum
infections collected annually from year 2000 to 2006 in
Kilombero/Ulanga. Signiﬁcant increase of the frequencies of
resistant dhfr and dhps haplotypes was observed after the
change of the National antimalarial guidelines from ﬁrst-
line CQ to ﬁrst-line SP. Clearly, changes of drug use policies
implementedduringtheconductofthisstudyhadimpacton
the genetic determinants of SP resistance.
4.1. Policy and Genetic Change. The study has demonstrated
that the inﬂuence of the national antimalarial treatment
policy change on the genetic composition of the malaria
parasite population was profound. Dhfr and dhps allele
frequency did not change signiﬁcantly during 12 months
(year 2000 to 2001) of CQ as ﬁrst-line and SP as second-
line, but after the switch to SP as ﬁrst-line treatment (year
2001 to 2002), the frequency of the triple mutant dhfr
allele increased from 31%–52%, while the frequency of the
double mutant dhps allele increased 3-fold. A combination
of these alleles is predictive of in vivo failure of SP treatment
[5, 6, 27], and the rapid increase of this genotype from
5%–29% between 2001-2002 suggests that the outlook for
SP eﬃcacy in this region was deteriorating. In fact, this
observation was borne out by the results of SP treatment
eﬃcacy monitoring in south-eastern Tanzania during 2003
which found that 49% of SP treatments failed by day
28 [28]. Due to this high rate of SP resistance, national
policy decision was switched to the recommended ﬁrst-
line treatment to artemether and lumefantrine in 2006. The
observed escalation of SP resistance alleles is attributed to
the policy change which brought about immediate shift in
treatment practice, characterised by increased demand of
SP both in the public and private sector leading to intense
SP drug pressure [12]. Again, because the change of policy
was nation wide, the same SP pressure was likely applying
to the districts surrounding the study area, narrowing the
likelihood of signiﬁcant higher selection and hence ﬂow of
resistant parasites from the neighbouring districts to the
study area.
4.2. Correlation between the Trend of SP Usage and the Levels
of dhfr and dhps Resistance Alleles. Prior to the introduction
of SP as ﬁrst-line therapy (between 2000 and 2001), SP
was widely available for self treatment via purchase from
pharmacies, shops [29] as well as through formal health
facilities as the second-line treatment. The SP drug pressure
exerted during this period was only suﬃcient to maintain
dhfr and dhps resistance alleles at constant levels. By contrast,
following the introduction of SP as ﬁrst-line in 2001, there
was dramatic increase in SP use [29] leading to intense SP
pressure and escalation of dhfr and dhps resistance alleles.
Although SP is currently being replaced as a ﬁrst-line drug
for treatment of malaria in Tanzania and much of the rest of
Africa, it will continue to be used in intermittent preventive
treatment of infants and pregnant women [30]. The drug
pressure applied when SP is used solely in intermittent
programmes of treatment in infants and pregnant women
will probably more closely resemble the situation observed
between2000-2001,whenSPwassecond-linetreatmentthan
during the period it was used as the ﬁrst-line treatment. The
consequences of more restricted use for future eﬃcacy of
SP are therefore two fold. Firstly, rates of resistance allele
frequencychangearelikelytostabiliseasaresultofreduction
of SP selection pressure. Secondly, the reduction of selection
is predicted to disassociate the triple mutant dhfr allele and
double mutant dhps allele which will reduce the frequency of
highly pyrimethamine and sulphadoxine resistant parasites
in the P. falciparum population at large.
4.3. Linkage Disequilibrium. Direct observation such as
plasma drug levels in the patient gives the best direct
measure of drug selection in the population and it would
be interesting to examine this in comparison to the LD
measures. LD on the other hand is known to give a good in-
direct indication of SP selection pressure, and hence, the lack
of signiﬁcant LD in Kilombero/Ulanga population in 2000
and 2001 when CQ was the ﬁrst-line treatment conforms to
expectations. In 2002, however, the signiﬁcant LD emerged
indicating intensiﬁcation of drug pressure following country
wide distribution and use of the SP as the new ﬁrst-line
treatment [29]. Contrary to our expectations, just one year
of SP use as ﬁrst-line treatment, a noticeable decline in
the rate of increase of resistant dhfr and dhps alleles along
with decreasing signiﬁcance of the LD was observed and
continued in the rest of surveys. By 2006 the LD was
no longer signiﬁcant indicating that the SP drug selection
strength was insuﬃcient to keep the two alleles, the triple
dhfr and double dhps alleles in combination. To understand
the reason for the three phase pattern of progression of SP
resistance alleles observed in this study, we retrospectively
reviewed the process of policy change in Tanzania in 2001,
from CQ to SP ﬁrst-line treatment.
4.4. Changes in Government Guidelines and the Public
Response. In order to explain the underlying cause of
reduction of SP selection strength just one year after SP
ﬁrst-line adoption in Tanzania, we retrospectively reviewed
the process of policy change from CQ to SP ﬁrst line. The
study also examined retrospectively the public perception
and the role of media in informing the public, who are the
endpointconsumersofthepolicy.Accordingly,TheNational
Task Force on Antimalarial Drug Policy was formulated
in May 1999 as a subcommittee of the National Malaria
Advisory Committee (NMAC) in consultation with the East
African Network for Monitoring Antimalarial Treatments
(EANMAT) and WHO country oﬃce in Dar es Salaam [4].
On 23 July 1999, the task force developed a three-page
summary, drawing on evidence from clinical trials in the
sentinel sites. It was recommended that the decision to
change the policy should be interim because of increasing
evidence of high SP resistance in various parts of the country
such as Muheza and Kilombero districts [31]. After the
presentation of the new policy by the task force, a series
of news papers and some private radio stations began to
inform the public that CQ was no longer a recommendedMalaria Research and Treatment 7
drug for malaria treatment and that the government was
considering replacing it with a new drug. This information
caused public concern and debates erupted in diﬀerent
parts of the country about the rationality for the change
[4, 10, 11]. Those involved were the general public, the
research community, traders, the pharmaceutical industry,
and health-care providers in both the public and private
health facilities.
In an attempt to maintain public conﬁdence, the Gov-
ernment through the Ministry of Health gave out a press
release that indicated its stand concerning the treatment
guidelines to be followed while strategies were underway to
make an appropriate decision. Anecdotal evidence indicates
that many health professionals were unaware of the extent
of resistance to CQ and did not perceive an urgent need for
change [3].
While WHO recommends change to an alternative drug
when the treatment failure rates with the ﬁrst-line drug
reaches 25%, evidence from diﬀerent sentinel sites in the
country indicated that up to the time of policy change, CQ
treatment failure rate had already reached 52% (ranging
28%–72%),9.5%forSP(ranging6%–32%),whiletreatment
failure to other drugs such as AQ and Q was less than
4.6% (ranging from 3.5%–6%) [32]. More criticism ensued
between the Ministry of health, the local newspapers and the
research community on the eﬀectiveness of CQ. While the
public were advised to remain patient until the government
gathered suﬃcient evidence, researchers continued to dis-
seminate information indicating high levels of resistance and
suggesting for replacement of CQ with a more suitable drug
[4]. The government’s oﬃcial announcement of the policy
change came out of the media in 2000 although the actual
implementation oﬃcially started on 1st August 2001.
Clearly, there were big diﬀerences between diﬀerent
actors which spurred a great deal of challenges in the long
term uptake and support of the new policy down to the
communities. A study conducted in 2002 (one year of policy
adoption)reportedwidespreadfearandnegativeperceptions
about the use of SP [11]. Lack of educational campaign
from the Ministry of Health and domination of the media
with reports of adverse SP reaction, led to a growing trend
of lack of conﬁdence in SP use as demonstrated by the
public [10, 11]. The trend of events in the policy adoption
and implementation described here corroborates well with
the genetic events described in Figures 1 and 2. Within the
ﬁrst year of policy implementation, usage of SP was highest
(intense selection pressure with signiﬁcant positive LD in the
population). However, as adverse reaction to SP continued
to mount, and were exaggerated by the media, the drug
gradually lost popularity. It is also very possible that as SP
resistance intensiﬁed over time, an increasing number of SP
users reverted to alternative antimalarials again reducing SP
selection pressure.
5. Conclusions andRecommendations
The national policy change brought about an immediate
shift in treatment practice and this in turn had a highly
signiﬁcant impact on drug pressure. This shows that even
in rural areas where access to treatment is imperfect and
treatment coverage relatively low, ﬁrst-line SP selection is
suﬃciently strong to rapidly change the genetic composition
oftheparasitepopulationinoneyear.Furthermore,selection
applied was strong enough to overcome recombination
pressure and create linkage disequilibrium between the
unlinked genetic determinants of resistance to the two
co-administered drugs (sulfadoxine and pyrimethamine),
showing that recombination is not a barrier to the evolution
of multidrug resistance in high endemicity settings.
The data presented here show that both the media and
health workers play a key role to modify the political tech-
nical and social values of policy adoption success. The need
to consider when and how research information should be
communicatedbetweendiﬀerent stake holders is very crucial
and should enable avoiding similar dilemmas in future.
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